Poonawalla group acquires Dutch global vaccine companyJuly 5th, 2012 - 5:31 am ICT by IANS
Pune, July 4 (IANS) Serum Institute of India, the flagship company of the over $1 billion Poonawalla Group vaccine company, Wednesday announced the acquisition of Bilthoven Biologicals of the Netherlands, a company official said.
Through the acquisition, the Poonawalla Group will get access to technology and expertise for making the Salk injectable polio vaccine.
This first overseas acquisition by the Poonawalla Group will also provide the Group and Serum Institute an important manufacturing base in Europe with access to the important European and US markets.
“This acquisition will significantly strengthen our position in the global vaccines market, while giving us access to the technology and production facility of Injectable Polio Vaccine (Salk), which is the only logical solution available to the world for the eradication of polio,” said Cyrus Poonawalla, Chairman of the Poonawalla Group and Serum Institute, while announcing the acquisition.
“More importantly it also gives the Poonawalla Group an important operational and strategic beachhead in Europe and the US, with the important manufacturing base in the Netherlands. This will also significantly enhance our earlier offerings in the paediatric vaccines segment,” he added.
Bilthoven Biologicals is located in the city of Bilthoven near Amsterdam. The manufacturing facility is spread over 20 acres and employs over 200 people. The facility has a manufacturing capacity of over 20 million doses of vaccines in a year and the company sells these vaccines to Europe and developing countries.
Sharing the future outlook for the company, Adar Poonawalla, Executive Director of the Poonawalla Group said that the group is committed to investing over Euros 70-80 million over the next three years to augment the infrastructure and enhance the manufacturing capacity of the Bilthoven’s facilities.
“Serum Institute has one of the world’s largest vaccine manufacturing facilities at Pune, India and with this second manufacturing facility based in Europe, the company aims to access the developed markets of Europe and USA for its existing and future products in the pipeline,” he said.
- Pune firm slashes pentavalent vaccine prices 60 percent - Jun 13, 2011
- Uflex assigns $250 mn for growth, eyes $2-bn revenue by 2015 - Sep 06, 2012
- Indian firm joins Nigeria's polio battle (With Images) - Feb 23, 2012
- Hyderabad foundation gets $100,000 grant for polio vaccine - May 10, 2012
- India's Bharat Biotech to sell $1 diarrhoea vaccine - Jun 06, 2011
- Indian vaccine to save 250 million lives in Africa - Mar 01, 2011
- Italian firm Sogefi to expand capacity in India - Jul 06, 2012
- Racold Thermo eyes Rs.150 crore market - Jun 20, 2012
- Polio cases in Pakistan worry global agencies - May 15, 2011
- Lavazza plans to make India its second biggest coffee market - Jan 28, 2011
- Vaccine makers to lobby for higher immunization coverage - Sep 15, 2010
- India faces polio threat from Pakistan: Minister - Dec 20, 2011
- US AptarGroup expanding presence in India - Oct 27, 2011
- India-made H1N1 vaccine launched (Lead) - Jun 03, 2010
- Ranbaxy boosts presence in Africa with malaria drug - May 11, 2012
Tags: 1 billion, beachhead, biologicals, cyrus poonawalla, developing countries, eradication, executive director, flagship company, july 4, logical solution, manufacturing facilities, offerings, overseas acquisition, paediatric vaccines, polio, polio vaccine salk, pune india, segment, serum institute of india, vaccine company